Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference

Rhea-AI Summary

Foghorn Therapeutics Inc. (Nasdaq: FHTX) will present at Cowen’s 43rd Annual Health Care Conference from March 6-8, 2023, in Boston, MA. The company is focused on developing a new class of medicines through its Gene Traffic Control® platform, primarily targeting oncology. CEO Adrian Gottschalk will discuss their leukemia panel on March 8 at 12:50 p.m. ET. A webcast of the panel will be available on the company's website for up to 30 days. Foghorn's innovative approach aims to alter gene expression to treat serious diseases, enhancing the lives of many patients.

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate at Cowen’s 43rd Annual Health Care Conference, which is taking place March 6–8, 2023, at the Boston Marriott Copley Place in Boston, MA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Leukemia panel date and time: Wednesday, March 8, 12:50 p.m. ET

Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the panel here.

A webcast of the panel can also be accessed under “Events & Presentations” in the Investors section of Foghorn’s website, www.foghorntx.com, and will be available for up to 30 days.

About Foghorn Therapeutics
Foghorn^® Therapeutics Inc. is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. Foghorn is developing multiple product candidates in oncology. For more information about Foghorn, visit our website at www.foghorntx.com, and follow us on Twitter and LinkedIn.

Contact:

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com

Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com

Michael Lampe, ScientPR (Media) 
michael@scientpr.com 

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com

FAQ

What is the date of Foghorn Therapeutics' presentation at the Cowen Health Care Conference?

Foghorn Therapeutics will present at the Cowen Health Care Conference on March 8, 2023.

Who is presenting for Foghorn Therapeutics at the Cowen Health Care Conference?

Adrian Gottschalk, the President and CEO, will present for Foghorn Therapeutics.

What is the focus of Foghorn Therapeutics' Gene Traffic Control platform?

The Gene Traffic Control platform focuses on developing medicines that correct abnormal gene expression, with an initial emphasis on oncology.

When will the leukemia panel discussion take place during the Cowen Health Care Conference?

The leukemia panel discussion will occur on March 8, 2023, at 12:50 p.m. ET.

Where can I access the webcast of Foghorn Therapeutics' panel discussion?

The webcast can be accessed in the 'Events & Presentations' section of Foghorn's website for up to 30 days following the conference.